-
FDA clears labeling change for non-drowsy Claritin
Jan 24, 08 FDA ApprovalsSchering-Plough said that the FDA has approved additional labeling for Claritin, which clearly tells consumers that the non-drowsy over-the-counter medication relieves allergy symptoms caused by both indoor or perennial or year-round and outdoor or seasonal allergies.
John O’Mullane, group vice-president, R&D, Schering-Plough Consumer Health Care, said: “Schering-Plough is pleased that the FDA has approved the change to the Claritin label to help us to communicate to consumers that Claritin works hard to relieve both indoor and outdoor allergies.”
Also in this section:
Subscribe to the "News" RSS Feed 
TOP ۞
